新型载药微球栓塞治疗肝脏肿瘤的初步经验.docVIP

精品论文 参考文献 新型载药微球栓塞治疗肝脏肿瘤的初步经验 （浙江大学医学院附属第一医院肝胆胰介入中心 浙江 杭州 310003） 【摘要】 目的：观察新型载药栓塞微球（Hepasphere）治疗肝脏肿瘤的安全性及其近期临床疗效。方法：12 例肝脏肿瘤患者在肝动脉化疗栓塞术中使用Hepasphere微球栓塞，对患者临床资料、影像随访资料、介入治疗的并发症和预后等情况进行总结和分析。采用mRESCIST标准，术后每月随访一次。12例肝脏肿瘤患者中，男性7例，女性5例，年龄43～69岁，中位年龄51岁。12例患者共行22次TACE。其中原发性肝癌5例，转移性肝癌7例（原发肿瘤为：结直肠癌3例，胆囊癌1例，神经内分泌癌1例，胰腺癌1例，胃癌1例）。结果：12例患者随访7～12月，中位随访时间为9月，根据mRESCIST标准，3月疾病缓解率为50%，疾病控制率为83.3%，6月疾病缓解率为33.3%，疾病控制率为75%。所有患者均未出现胆汁漏并发感染、肝脓肿、腹腔出血、肿瘤破裂出血及消化道出血等严重并发症。少数患者术后当天腹痛较重，需盐酸哌替啶止痛，其他患者腹痛较轻。结论：应用新型栓塞微球（Hepasphere）治疗肝脏肿瘤的近期临床疗效及安全性均较好，远期效果仍需大量病例进一步观察。 【关键词】 TACE；肝脏肿瘤；Hepasphere微球；载药微球 【中图分类号】R73 【文献标识码】A 【文章编号】2095-1752（2016）02-0156-02 Embolization with Hepasphere drug eluting microsphere for treatment of Liver cancer Zhou Guanhui, Sun Junhui, Zhang Yuelin, Nie Chunhui, Zhou Tanyang, Zhu Tongyin, Wu Jian, Wang Weilin, Zheng Shusen. The Center of Hepatobiliary and Pancreatic Intervention, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China 【Abstract】Objective To evaluate the therapeutic results and safety of treatment for liver cancer with a new kind of microsphere. Methods 12 patients with liver cancer underwent TACE with Hepasphere microsphere. The clinical data, imaging follow-up data, complications of interventional treatment and prognosis were summarized and analyzed. Local response was evaluated with modified response evaluation criteria in solid tumors （mRECIST）. There were 7 male, 5 female and the median age was 51 years. A total of 22 TACE procedures were performed in 12 patients. There were 5 patients with HCC and 7 patents with liver metastases （the primary tumor sites included: colorectal ca, neuroendocrine ca, gallbladder ca, pancreatic ca, gastric ca）. Results The follow up period ranged from 7 months to 12 months（mid 9 months）. The 3-month objective response rate was 50%, and disease control rate was 83.3%. The 6-month objective response rate was 33.3%, and disease control rate w